Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 4/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1529562 | 1.00 | ATM (0.71) | ATMCYP3A4MAPK1APPCTSS | |
| SCHEMBL257912 | 1.00 | ATM (0.71) | ATMCYP3A4MAPK1APPCTSS | |
| SCHEMBL7857967 | 0.95 | ATM (0.65) | ATMCYP3A4MAPK1APPCTSS | |
| SCHEMBL15521493 | 0.92 | CTSS (0.62) | ATMCYP3A4MAPK1APPCTSS | |
| SCHEMBL1531592 | 0.92 | CTSS (0.62) | ATMCYP3A4MAPK1APPCTSS | |
| SCHEMBL1531589 | 0.92 | CTSS (0.62) | ATMCYP3A4MAPK1APPCTSS | |
| SCHEMBL15159951 | 0.90 | ATM (0.73) | ATMCYP3A4APPCTSSCTSK | |
| SCHEMBL2291516 | 0.90 | ATM (0.59) | ATMCYP3A4MAPK1APPCTSS | |
| SCHEMBL13669577 | 0.90 | CTSS (0.67) | ATMCYP3A4MAPK1APPCTSS | |
| SCHEMBL20249542 | 0.89 | ATM (0.59) | ATMCYP3A4MAPK1APPCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 571 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | claimed |
| CN-117623988-A | Synthesis method of N-Boc-L-phenylalaninol | 常州锐博生物科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-116730873-A | Synthesis method of N-Boc-L-phenylalaninol | 常州锐博生物科技有限公司 | 2023-09-12 | — | — | CN | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| EP-0820438-B1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | SK CORP (KR) | 2001-06-20 | — | — | EP | claimed |
| EP-0820438-A1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1998-01-28 | — | — | EP | claimed |
| WO-1996032375-A1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1996-10-17 | — | — | WO | claimed |
| US-4978744-A | Synthesis of dolastatin 10 | ARIZONA BOARD OF REGENTS (US) | 1990-12-18 | — | — | US | claimed |
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20250353853-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-11-20 | — | — | US | disclosed |
| EP-4638446-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4532476-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-04-09 | — | — | EP | disclosed |
| US-20250110407-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD, AND RESIST BASE FILM FORMING COMPOSITION | JSR CORPORATION (JP) | 2025-04-03 | — | — | US | disclosed |
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-4820712-A | Sparsomycin (SC-RS) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (SC-RS) compounds | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 1989-04-11 | — | — | US | disclosed |
| WO-1988007053-A1 | RENIN INHIBITORS CONTAINING A CYCLOPROPYL AMINO ACID AND/OR A CYCLOALKYL TRANSITION-STATE ANALOGUE | THE UPJOHN COMPANY (US) | 1988-09-22 | — | — | WO | disclosed |
| EP-0231919-A2 | N-Heterocyclic alcohol renin inhibitors | E.R. Squibb & Sons, Inc. (US) | 1987-08-12 | — | — | EP | disclosed |
| EP-0218688-A1 | DIHALO-STATINE SUBSTITUTED RENIN INHIBITORS. | UPJOHN CO (US) | 1987-04-22 | — | — | EP | disclosed |
| US-4631270-A | THIOMETHYLENE REPLACEMENTS | RESEARCH CORPORATION (US) | 1986-12-23 | — | — | US | disclosed |
| WO-1986006379-A1 | DIHALO-STATINE SUBSTITUTED RENIN INHIBITORS | THE UPJOHN COMPANY (US) | 1986-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | ATM 2668/4885CYP3A4 4330/4885MAPK1 2218/4885 |
| US-20250353853-A1 | FLAVIVIRUS INHIBITORS | SPINT2, EIF2AK2, DDX5 | ATM 4645/4885CYP3A4 1757/4885MAPK1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.